	in the same of the same of the	range spil i i in		C	8	. 79 11 1 2 19 10 10	
INFORM	ATION DISCLOSURE C	Attorney Docket 04	4508-5001	Application	No. 09/762,261		
TO E Several sheets if necessary)			Applicants: Gerald Quinnan et B Page 1 of 1				
PTO Form 1449			Filing Date: February 5, 2001 Group Art Unit: 1653				
JAM	× ×	U.S. PAT	TENT DOCUMENTS			Filing Date	
MODERT & TRADE	Document No.	Date	Name	Class	Sub-Class	Fining Date	
HOW I THE	Document						
				<u> </u>			
FOREIGN PATENT DOCUMENTS Class Sub-Class Translation							
	Document No.	Date	Country	Class	Sub-Class	Translation	
	Document			ļ			
		1					
		TATES (Included	ling Author, Title, Dat	e, Pertinen	t Pages, etc.)		
						against diverse	
عمر التيار aa	Cotropia et al. (1996) A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:221-232						
7/	laboratory isolates, J. Acquir. Immune Defic. Syndr. Hum. Retrovitor. 12.221-232 Hioe et al. (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies,						
1	Int. Immunol. 9:1281-1290						
- lax	Int. Immunol. 9:1281-1290 Int. Immunol. 9:1281-1290 Moore et al. (1993) Probing the structure of the V2 domain of human immunodeficiency virus type 1 surfiglycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V1 glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V1 glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V1 glycoprotein gp120 with a panel of eight monoclonal antibodies:						
	olycoprotein gp120 with	dycoprotein gp120 with a panel of eight monocional and eight monocional eight monocional and eight monocional and eight monocional and					
	domains, J. Virol. 67:6136-6151 Muster et al. (1993) A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1,						
a	Muster et al. (1993) A conserved neutralization opto-p						
1	J. Virol. 67:6642-6647 Sabri et al. (1996) Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some Patroviruses 12:855-858						
aè	Sabri et al. (1996) Lack of concention set of the Sabri et al. (1996) Lack of concention set al. (1996) Lack						
asy	That et al. (1993) Characterization of conserved number in minutes of the conserved number of the cons						
1 1 "7	epitopes exposed upon gp120-CD4, J. Virol. 67:3978-3988 Thali et al. (1994) Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus Thali et al. (1994) Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus						
ag	Thali et al. (1994) Resistance to neutralization by bloadly least 1 Virol 68:674-680						
	type-1 gp120 glycoprotein conferred by a gp41 amino acid change, 3. Vitol. 03.074-066 type-1 gp120 glycoprotein conferred by a gp41 amino acid change, 3. Vitol. 03.074-066 Trkola et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human Trkola et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human						
ah	immunodeficiency virus type-1, J. viroi. 70.1100 1100						
ai 🗡 ai	VanCott et al. (1997) Antibodies with specificity to native gp120 and neutralization activity against VanCott et al. (1997) Antibodies with specificity to native gp120 and neutralization activity against VanCott et al. (1997) Antibodies with specificity to native gp120 and neutralization activity against variation with oligomeric gp160, J. Virol. 71:4319-4330 immunodeficiency virus type-1 isolates elicited by immunization with oligomeric gp160, J. Virol. 71:4319-4330 immunodeficiency virus type-1 isolates elicited by immunization of the principal neutralization domain of HIV-1,						
A N	immunodeficiency virus type-1 isolates elicited by immunization with originaters gp-3. Zwart et al. (1991) Immunodominance and antigenic variation of the principal neutralization domain of HIV-1,						
94	J. Virol. 181:481-489.	- D	- 100 - 100			Marie III -	
Examiner	-1	Da	te Considered				
			alak				
due	nitial if reference considered	d whether or not	citation is in conforman	ce with MP	EP 609; draw line	through citation if no	
Examiner: In	nitial if reference considered considered included in the considered. Included in the considered in th	ude conv of this f	form with next communi	cation to ap	plicant.		
in conforman	ice and not considered. Their	accopy of the					

JC05 Rec'd PCT/PTO Attorney Docket INFORMATION DISCLOSURE CITATION 044508-5001 Applicants: (Use several sheets if necessary) Gerald V. Quinnan, Jr. et al. Page 1 of 1 Group Art Unit: Not assigned PTO Form 1449 Filing Date: February 5, 2001 U.S. PATENT DOCUMENTS Class Sub-Class Filing Date Initial Document No. Date Name SI 6/15/94 5,622,933 4/22/97 Sabatier et al. 514 16 875 350 6/7/95 5/26/98 530 5,756,674 Katinger et al. 8%-5,439,809 8/8/95 Haynes et al. 435 69.3 6/15/92 FOREIGN PATENT DOCUMENTS Class Sub-Class **Translation** Document No. Date Country OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through Examiner: citation if not in conformance and not considered. Include copy of this form with next communication to applicant.